ClinicalTrials.gg
Active, not recruitingNCT07281495Updated Mar 20, 2026

Taldefgrobep Alfa in Adults With Overweight and Obesity

A Phase 2 interventional study of Taldefgrobep Alfa and Placebo in Obesity and Overweight, sponsored by Biohaven Therapeutics Ltd.. Active, not recruiting at 20 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Biohaven Therapeutics Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.

02

Conditions studied

  • Obesity
  • Overweight

Keywords

  • myostatin
  • activin
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 150 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Biohaven Therapeutics Ltd. is the lead sponsor of 20 studies on the registry; 9 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. a. > 30 kg/m2 and BMI \< 42 kg/m2, OR b. BMI ≥ 27 kg/m2 and BMI \<30 kg/m2 with at least one weight-related co-morbidity
  2. History of at least one self-reported unsuccessful dietary effort to lose body weight.
  3. Stable body weight and stable physical activity within 3 months prior to screening per participant self-report.
  4. All participants must adhere to protocol requirements

Key Exclusion Criteria:

  1. History of diabetes, including individuals with a of ≥ 6.5% at Screening
  2. Non-ambulatory participants, defined as unable to take at least 10 steps independently.
  3. Females currently pregnant or breastfeeding, or who intend to become pregnant or to breastfeed.
  4. Participation in another clinical trial while participating in this clinical trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Taldefgrobep Alpha once weekly

    Drug: Taldefgrobep Alfa

  • Placebo comparator
    Placebo once weekly

    Drug: Placebo

  • Experimental
    Taldefgrobep Alpha once every 4 weeks

    Drug: Taldefgrobep Alfa

  • Placebo comparator
    Placebo once every 4 weeks

    Drug: Placebo

Interventions

  • Subcutaneous injection administered once each week

    Also known as: BHV-2000

  • DrugPlacebo

    Subcutaneous injection (matching placebo) administered once each week

  • Subcutaneous injection administered once every 4 weeks

    Also known as: BHV-2000

  • DrugPlacebo

    Subcutaneous injection (matching placebo) administered once every 4 weeks

06

What researchers measure

Primary outcomes

  1. Percent change in total body weight from Baseline to Week 24

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Percent change in total body fat mass from Baseline to Week 24

    Time frame: Baseline to Week 24

  2. Percent change in total body lean mass from Baseline to Week 24

    Time frame: Baseline to Week 24

  3. Number of participants with death, SAEs, AEs considered related to study drug, moderate and severe AEs, and Grade 3 to 4 laboratory abnormalities

    Time frame: Through week 24

07

Study locations

20 sites
  • Site-001
    Chula Vista, California 91911, United States
  • Site-014
    Montclair, California 97163, United States
  • Site-011
    Sacramento, California 95821, United States
  • Site-018
    Tustin, California 92780, United States
  • Site-020
    Orlando, Florida 32804, United States
  • Site-008
    Palm Springs, Florida 33461, United States
  • Site-015
    St. Petersburg, Florida 33704, United States
  • Site-007
    Chicago, Illinois 60625, United States
  • Site-016
    Indianapolis, Indiana 46254, United States
  • Site-010
    Baton Rouge, Louisiana 70808, United States
  • Site-009
    Metairie, Louisiana 70006, United States
  • Site-006
    City of Saint Peters, Missouri 63303, United States
  • Site-003
    Springfield, Missouri 65807, United States
  • Site-019
    Monroe, North Carolina 28112, United States
  • Site-002
    Fargo, North Dakota 58104, United States
  • Site-017
    North Charleston, South Carolina 29405, United States
  • Site-005
    Austin, Texas 78745, United States
  • Site-012
    McKinney, Texas 75069, United States
  • Site-013
    San Antonio, Texas 78229, United States
  • Site-004
    Arlington, Virginia 22205, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 10 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 15, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07281495
Lead sponsor
Biohaven Therapeutics Ltd.
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Nov 24, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Mar 20, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taldefgrobep alfa

Start the discussion